4 November 2013Biotechnology

New frontiers: potential barriers to patenting induced totipotent stem cell technology

It has for some years been possible to create pluripotent stem cells (stem cells capable of differentiating into many, but not all, other cell types of the body) from fully differentiated adult cells (so called ‘induced pluripotent stem cells’ [iPS cells]).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sanofi subsidiary fends off $450m trade secrets case

Pfizer infringed haemophilia therapy patent, says court

Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar

10x Genomics counsel: ‘Winning cases is a top priority’

HR, lobbying and business strategy…all in a day’s work for today’s counsel

LSPN Fall: Gilead GC shares top drafting tips

New frontiers: potential barriers to patenting induced totipotent stem cell technology

Editor's picks

Editor's picks

More features